|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jung KW, Won YJ, Hong S, Kong HJ and Lee
ES: Prediction of cancer incidence and mortality in Korea, 2020.
Cancer Res Treat. 52:351–358. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ogino S and Goel A: Molecular
classification and correlates in colorectal cancer. J Mol Diagn.
10:13–27. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li D: Recent advances in colorectal cancer
screening. Chronic Dis Transl Med. 4:139–147. 2018.PubMed/NCBI
|
|
6
|
Di Croce L, Raker VA, Corsaro M, Fazi F,
Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, et
al: Methyltransferase recruitment and DNA hypermethylation of
target promoters by an oncogenic transcription factor. Science.
295:1079–1082. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ko M, An J and Rao A: DNA methylation and
hydroxymethylation in hematologic differentiation and
transformation. Curr Opin Cell Biol. 37:91–101. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jones PA: Functions of DNA methylation:
Islands, start sites, gene bodies and beyond. Nat Rev Genet.
13:484–492. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tahiliani M, Koh KP, Shen Y, Pastor WA,
Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L and
Rao A: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in
mammalian DNA by MLL partner TET1. Science. 324:930–935. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jin SG, Jiang Y, Qiu R, Rauch TA, Wang Y,
Schackert G, Krex D, Lu Q and Pfeifer GP: 5-Hydroxymethylcytosine
is strongly depleted in human cancers but its levels do not
correlate with IDH1 mutations. Cancer Res. 71:7360–7365. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Haffner MC, Chaux A, Meeker AK, Esopi DM,
Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C,
Nelson WG, et al: Global 5-hydroxymethylcytosine content is
significantly reduced in tissue stem/progenitor cell compartments
and in human cancers. Oncotarget. 2:627–637. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang W and Guan KL: AMP-activated protein
kinase and cancer. Acta Physiol (Oxf). 196:55–63. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hardie DG: AMP-activated/SNF1 protein
kinases: Conserved guardians of cellular energy. Nat Rev Mol Cell
Biol. 8:774–785. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marin TL, Gongol B, Zhang F, Martin M,
Johnson DA, Xiao H, Wang Y, Subramaniam S, Chien S and Shyy JY:
AMPK promotes mitochondrial biogenesis and function by
phosphorylating the epigenetic factors DNMT1, RBBP7, and HAT1. Sci
Signal. 10:eaaf74782017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu D, Hu D, Chen H, Shi G, Fetahu IS, Wu
F, Rabidou K, Fang R, Tan L, Xu S, et al: Glucose-regulated
phosphorylation of TET2 by AMPK reveals a pathway linking diabetes
to cancer. Nature. 559:637–641. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Warburg O, Wind F and Negelein E: The
metabolism of tumors in the body. J Gen Physiol. 8:519–530. 1927.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ríos M, Foretz M, Viollet B, Prieto A,
Fraga M, Costoya JA and Señarís R: AMPK activation by oncogenesis
is required to maintain cancer cell proliferation in astrocytic
tumors. Cancer Res. 73:2628–2638. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Park HU, Suy S, Danner M, Dailey V, Zhang
Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, et al:
AMP-activated protein kinase promotes human prostate cancer cell
growth and survival. Mol Cancer Ther. 8:733–741. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Baba Y, Nosho K, Shima K, Meyerhardt JA,
Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS
and Ogino S: Prognostic significance of AMP-activated protein
kinase expression and modifying effect of MAPK3/1 in colorectal
cancer. Br J Cancer. 103:1025–1033. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Buckendahl AC, Budczies J, Fiehn O,
Darb-Esfahani S, Kind T, Noske A, Weichert W, Sehouli J, Braicu E,
Dietel M and Denkert C: Prognostic impact of AMP-activated protein
kinase expression in ovarian carcinoma: Correlation of protein
expression and GC/TOF-MS-based metabolomics. Oncol Rep.
25:1005–1012. 2011.PubMed/NCBI
|
|
22
|
Tsavachidou-Fenner D, Tannir N, Tamboli P,
Liu W, Petillo D, The B, Mills GB and Jonasch E: Gene and protein
expression markers of response to combined antiangiogenic and
epidermal growth factor targeted therapy in renal cell carcinoma.
Ann Oncol. 21:1599–1606. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Okoshi R, Ozaki T, Yamamoto H, Ando K,
Koida N, Ono S, Koda T, Kamijo T, Nakagawara A and Kizaki H:
Activation of AMP-activated protein kinase induces p53-dependent
apoptotic cell death in response to energetic stress. J Biol Chem.
283:3979–3987. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jang T, Calaoagan JM, Kwon E, Samuelsson
S, Recht L and Laderoute KR: 5′-AMP-activated protein kinase
activity is elevated early during primary brain tumor development
in the rat. Int J Cancer. 128:2230–2239. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kola B, Boscaro M, Rutter GA, Grossman AB
and Korbonits M: Expanding role of AMPK in endocrinology. Trends
Endocrinol Metab. 17:205–215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mistry T, Digby JE, Desai KM and Randeva
HS: Obesity and prostate cancer: A role for adipokines. Eur Urol.
52:46–53. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rankin EB and Giaccia AJ: The role of
hypoxia-inducible factors in tumorigenesis. Cell Death Differ.
15:678–685. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hadad SM, Baker L, Quinlan PR, Robertson
KE, Bray SE, Thomson G, Kellock D, Jordan LB, Purdie CA, Hardie DG,
et al: Histological evaluation of AMPK signalling in primary breast
cancer. BMC Cancer. 9:3072009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen P, Li K, Liang Y, Li L and Zhu X:
High NUAK1 expression correlates with poor prognosis and involved
in NSCLC cells migration and invasion. Exp Lung Res. 39:9–17. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Suzuki A, Lu J, Kusakai G, Kishimoto A,
Ogura T and Esumi H: ARK5 is a tumor invasion-associated factor
downstream of Akt signaling. Mol Cell Biol. 24:3526–3535. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu
J, Xu ZD, Zhu HG, Ling ZQ, Ye D, et al: Tumor development is
associated with decrease of TET gene expression and
5-methylcytosine hydroxylation. Oncogene. 32:663–669. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang LY, Li PL, Wang TZ and Zhang XC:
Prognostic values of 5-hmC, 5-mC and TET2 in epithelial ovarian
cancer. Arch Gynecol Obstet. 292:891–897. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hemerly JP, Bastos AU and Cerutti JM:
Identification of several novel non-p.R132 IDH1 variants in thyroid
carcinomas. Eur J Endocrinol. 163:747–755. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pansuriya TC, van Eijk R, d'Adamo P, van
Ruler MA, Kuijjer ML, Oosting J, Cleton-Jansen AM, van Oosterwijk
JG, Verbeke SL, Meijer D, et al: Somatic mosaic IDH1 and IDH2
mutations are associated with enchondroma and spindle cell
hemangioma in Ollier disease and Maffucci syndrome. Nat Genet.
43:1256–1261. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Parsons DW, Jones S, Zhang X, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et
al: An integrated genomic analysis of human glioblastoma
multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rasmussen KD and Helin K: Role of TET
enzymes in DNA methylation, development, and cancer. Genes Dev.
30:733–750. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Guo X, Wang L, Li J, Ding Z, Xiao J, Yin
X, He S, Shi P, Dong L, Li G, et al: Structural insight into
autoinhibition and histone H3-induced activation of DNMT3A. Nature.
517:640–644. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Otani J, Nankumo T, Arita K, Inamoto S,
Ariyoshi M and Shirakawa M: Structural basis for recognition of
H3K4 methylation status by the DNA methyltransferase 3A
ATRX-DNMT3-DNMT3L domain. EMBO Rep. 10:1235–1241. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Boulard M, Edwards JR and Bestor TH:
FBXL10 protects Polycomb-bound genes from hypermethylation. Nat
Genet. 47:479–485. 2015. View Article : Google Scholar : PubMed/NCBI
|
